The ARHGEF1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HAP1 cells with targeted disruption of the ARHGEF1 gene. This product provides a heterogeneous pool of knockout cells generated by Cas9-mediated genome editing, offering a versatile loss-of-function model for investigating ARHGEF1-dependent signaling pathways. The polyclonal format maintains the inherent advantages of the near-haploid HAP1 background while allowing efficient ablation of the target gene without requiring single-cell cloning. This knockout model is particularly suited for studies where rapid generation of a mixed knockout population is desired for functional genomics, signaling pathway analysis, and drug target validation.
HAP1 is a human near-haploid cell line derived from the KBM-7 chronic myeloid leukemia line. Its near-haploid karyotype significantly simplifies genetic engineering, as the presence of a single copy of most genes ensures that CRISPR/Cas9-mediated gene disruption results in a functionally null phenotype without the need for biallelic targeting. HAP1 cells are widely used as a robust platform for genetic screens and isogenic knockout studies, offering consistent growth characteristics and easy transfection. The near-haploid nature also facilitates the generation of polyclonal knockout populations that lack functional gene expression, enabling straightforward phenotypic analysis in a physiologically relevant human context.
ARHGEF1 encodes p115-RhoGEF, a guanine nucleotide exchange factor that specifically activates RhoA downstream of G??12/13-coupled receptors. Upon stimulation by ligands such as lysophosphatidic acid (LPA), thrombin, or sphingosine-1-phosphate, ARHGEF1 catalyzes the exchange of GDP for GTP on RhoA. Activated RhoA-GTP then engages downstream effectors including ROCK1/2, which phosphorylate LIM kinase and myosin light chain (MLC), leading to cofilin inactivation and actin stress fiber polymerization. This cascade promotes focal adhesion assembly via interactions with paxillin, vinculin, and FAK, ultimately regulating cell migration, contractility, and angiogenesis. ARHGEF1 also links GPCR signaling to serum response factor (SRF)-mediated transcription through the MRTF-A cofactor, integrating extracellular cues with cytoskeletal and transcriptional responses.
In the HAP1 cellular context, disruption of ARHGEF1 provides a clean loss-of-function system to dissect RhoA-dependent processes. Because HAP1 cells express a single allele of ARHGEF1, the polyclonal knockout population exhibits uniform loss of p115-RhoGEF activity, enabling consistent readouts in functional assays. This model is invaluable for delineating the contributions of G??12/13?CRhoA signaling to cytoskeletal dynamics, adhesion, and migration independent of compensatory mechanisms. The knockout cells can be used to validate the specificity of pharmacological inhibitors targeting the RhoA/ROCK axis and to explore crosstalk between GPCR pathways and integrin-based adhesion complexes.
Typical research applications include RhoA GTPase activation assays, western blotting for phospho-MLC and cofilin, immunofluorescence for F-actin stress fibers, and quantitative analyses of cell migration and invasion. The cells are well-suited for haploid genetic screens to identify synthetic lethal interactions or modulators of ARHGEF1-related phenotypes. Additionally, they support drug target validation in cancer metastasis, angiogenesis, and cardiovascular disease contexts. Their use in co-immunoprecipitation studies facilitates mapping of ARHGEF1 interactions with G??12/13, RhoA, and other signaling partners. For further technical details or to request a sample, please contact Ascent Research.
